BioInsights - Improving the enrichment of mononuclear cells for CAR T cell therapies: the importance of platelet depletion

Improving the enrichment of mononuclear cells for CAR T cell therapies: the importance of platelet depletion

Cell & Gene Therapy Insights 2021; 7(10)1275;

10.18609/cgti.2021.170

Published: 19 October 2021
FastFacts
Isabelle Fusine

Watch the video or read the poster to learn:

  • Why optimal mononuclear cell enrichment is critical to the successful start of a standard autologous CAR-T manufacturing process
  • How a platelet removal step upstream rather than downstream of density gradient separation can reduce the amount of red blood cell contamination
  • Working with a closed and automated system for both platelet removal and density gradient separation minimizes the risk of contamination, operator variability, and errors, while also reducing procedure time

Isabelle Dalle Fusine is a trained biomedical engineer with 6 years of R&D experience in the cell and gene therapy field working in process development and new product introduction. In 2021 she joined the Global Product Marketing team as a Product Marketing Manager for Digital and Automation, where she is supporting the strategic roadmap for future solutions for the cell and gene therapy market, in close collaboration with our trusted customers, as well as academic and industry partners.